■在COVID-19大流行期间,由于隔离措施,选择性手术面临取消。这项研究的目的是评估面部整形和重建手术(FPRS)的体积,during,在全国范围的大流行之后。
■TriNetX研究网络从2017年到2022年确定了68,101,098名18岁以上的人进行了医疗保健互动。在每年的3月至8月期间比较了普通FPRS手术和程序的比率,与大流行封锁保持一致。
■与2019年大流行之前相比,2020年大流行高峰的整体手术量减少了-36.8%,特异性手术显着减少:隆鼻(-28.6%),鼻中隔成形术(-34.0%),除皱术(-54.9%),眼睑成形术(-40.7%),眉毛提升(-43.8%),外翻/内翻修复(-35.6%),上睑下垂修复(-45.6%),眼球下垂矫正(-29.9%),盖回缩校正(-36.8%),和脂肪切除术(-41.8%)(p<.001)。程序量亦减少28.6%,包括各种程序的减少:肉毒杆菌毒素A(-18.7%),面部填充剂(-40.7%),磨皮(-62.3%),化学果皮(-36.6%),和病灶内注射(-33.3%)(p<.001)。与2020年相比,2021年的总手术量增加了+75.0%,手术量增加了+61.3%:隆鼻(+81.0%),鼻中隔成形术(+74.7%),除皱术(+143.4%),眼睑成形术(+81.7%),眉头提升(+64.5%),外翻/内翻修复(+55.2%),上睑下垂修复(+62.7%),眼球矫正(+39.0%),盖回缩校正(+73.0%),脂肪切除术(+121.2%),肉毒杆菌毒素A(+52.4%),填料(+59.6%),磨皮(+91.8%),化学剥皮(+78.8%),和病灶内注射(+67.3%)(p<.001)。2022年,总手术率(+8.5%)和手术率(+12.8%)超过了2019年大流行前的水平(p<.001)。
■FPRS经历了大流行引起的显着下降,随后几年出现了显著的复苏,某些手术和程序超过大流行前的水平。
■4.
UNASSIGNED: During the COVID-19 pandemic, elective surgeries faced cancelations due to quarantine measures. The objective of this study was to assess facial plastic and reconstructive surgery (FPRS) volume before, during, and after the height of the pandemic on a national scale.
UNASSIGNED: The TriNetX Research Network identified 68,101,098 individuals aged 18+ with healthcare interactions from 2017 to 2022. Rates of common FPRS surgeries and procedures were compared during March-August of each year, aligning with the pandemic lockdown.
UNASSIGNED: Compared to immediately before the pandemic in 2019, the 2020 pandemic peak saw an overall surgical volume reduction of -36.8%, with specific surgeries decreasing significantly: rhinoplasty (-28.6%), septoplasty (-34.0%), rhytidectomy (-54.9%), blepharoplasty (-40.7%), brow lift (-43.8%), ectropion/entropion repair (-35.6%), repair of blepharoptosis (-45.6%), correction of lagophthalmos (-29.9%), correction of lid retraction (-36.8%), and lipectomy (-41.8%) (p < .001). The procedural volume also decreased by 28.6%, encompassing reductions in various procedures: botulinum toxin A (-18.7%), facial filler (-40.7%), dermabrasion (-62.3%), chemical peel (-36.6%), and intralesional injection (-33.3%) (p < .001). In contrast to 2020, 2021 witnessed an increase of +75.0% in total surgical and +61.3% procedural volume: rhinoplasty (+81.0%), septoplasty (+74.7%), rhytidectomy (+143.4%), blepharoplasty (+81.7%), brow lift (+64.5%), ectropion/entropion repair (+55.2%), repair of blepharoptosis (+62.7%), correction of lagophthalmos (+39.0%), correction of lid retraction (+73.0%), lipectomy (+121.2%), botulinum toxin A (+52.4%), filler (+59.6%), dermabrasion (+91.8%), chemical peel (+78.8%), and intralesional injection (+67.3%) (p < .001). In 2022, rates of total surgeries (+8.5%) and procedures (+12.8%) surpassed pre-pandemic levels from 2019 (p < .001).
UNASSIGNED: FPRS experienced significant pandemic-induced decreases, followed by a notable recovery in subsequent years, with certain surgeries and procedures surpassing pre-pandemic levels.
UNASSIGNED: 4.